Executive SummaryBiotech firm begins previously announced spin off of genetic testing subsidiary IG Labs via a 1.9 mil. share public offering at $7.50 per share on May 3. Upon completion of the offering, Genzyme will own approximately 56% of IG Labs. Oppenheimer & Company is the managing underwriter.
You may also be interested in...
On this week’s podcast, executive editor Shawn M. Schmitt shares expert tips and advice on how device makers can integrate the recently revised international risk management standard ISO 14971 into their quality systems.
Alpha Tau is looking to change the global radiation therapy paradigm. The Israeli start-up is developing Alpha DaRT, a novel technology for delivering alpha radiation for local tumor destruction.
Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.